| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Director | Common Stock | 55.5K | $1.94M | $35.03 | Oct 31, 2025 | Direct |
| FATE THERAPEUTICS INC | Director | Stock Option (Right to Buy) | 40K | $109K | $2.73 | Jun 7, 2024 | Direct |
| aTYR PHARMA INC | Director | Common Stock | 56K | $98K | $1.75 | May 30, 2024 | Indirect |
| ADC Therapeutics SA | Director | Common Shares | 40K | $53.6K | $1.34 | Jun 3, 2025 | Direct |
| ADC Therapeutics SA | Director | Stock Options (Right to Buy) | 80K | Jun 3, 2025 | Direct | ||
| aTYR PHARMA INC | Director | Stock Option (right to buy) | 50K | May 1, 2025 | Direct | ||
| Travere Therapeutics, Inc. | Director | Stock option (right to buy) | 19.5K | May 15, 2025 | Direct | ||
| Travere Therapeutics, Inc. | Director | Director stock option (right to buy) | 0 | Oct 31, 2025 | Direct |